PDCD1 and neoplasm: The short duration of chemotherapy was assumed to be sufficient for enhancing the anti-tumor efficacy of PD-1 blockade by promoting immunogenic death of tumor cells and implementing pro-immunogenic changes in the tumor microenvironment (TME), but inadequate to negatively affect immune cells, especially the T cells.